Miscellaneous (e.g., Hydrocarbons, Etc.) Patents (Class 514/789)
-
Patent number: 11869633Abstract: The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention.Type: GrantFiled: December 14, 2018Date of Patent: January 9, 2024Assignee: The Board of Trustees of the University of IllinoisInventors: Ravishankar Krishnan Iyer, Arjun Prasanna Athreya, Richard Merle Weinshilboum, Liewei Wang, William Victor Bobo, Mark Andrew Frye
-
Patent number: 11747346Abstract: The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).Type: GrantFiled: September 2, 2016Date of Patent: September 5, 2023Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Alfred Garfall, Alex Ganetsky, Saar Gill, Simon Lacey, Jan J. Melenhorst, David Teachey, Eric Lancaster, Adam David Cohen, Pamela Shaw
-
Patent number: 11738019Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: July 10, 2020Date of Patent: August 29, 2023Assignee: Enanta Pharmaceuticals, Inc.Inventors: Joseph Panarese, Samuel Bartlett, Dexter Davis, Nathaniel Kenton, Yat Sun Or
-
Patent number: 11726089Abstract: Methods are provided for assaying neoplastic cells and/or neoplasia-related cells. Aspects of the methods involve detecting heterogeneity, per cell programmed-death ligand 1 (PD-L1) expression, and/or proliferation of neoplasia and/or neoplasia-related cells. Aspects of the methods include cytometrically assaying a labeled cell suspension to quantify per cell heterogeneity, per cell PD-L1 expression, proliferation, and/or other parameters to detect whether a neoplastic cell is present in the neoplasia sample. Aspects of the provided methods also include treating a subject based on the outcome of such an assay. In addition, kits that find use in practicing the subject methods are also provided.Type: GrantFiled: January 2, 2019Date of Patent: August 15, 2023Assignee: IncellDx, Inc.Inventors: Bruce K. Patterson, Amanda Noel Chargin, Keith Shults
-
Patent number: 11677973Abstract: The method relates to harmonization between affine mode and other inter coding tools mode. The method for video processing includes acquiring, during a conversion between a current block and a bitstream representation of the current block, an indication of the current block, where the indication indicates whether a merged affine model of the current block should be modified, and performing, at least based on the indication, the conversion between the current block and the bitstream representation of the current block.Type: GrantFiled: May 14, 2021Date of Patent: June 13, 2023Assignees: BEIJING BYTEDANCE NETWORK TECHNOLOGY CO., LTD, BYTEDANCE INC.Inventors: Kai Zhang, Li Zhang, Hongbin Liu, Yue Wang
-
Patent number: 11535895Abstract: The present invention provides a method of predicting whether a pulmonary nodule in a subject is benign or non-small cell lung cancer, comprising obtaining the results of an assay that measures an expression level of miR205-5p in a plasma sample from the subject; obtaining the results of an assay that measures an expression level of miR126 in a plasma sample from the subject; obtaining the results of an assay that provides a size of the pulmonary nodule in the subject; and calculating a probability value based on the combination of the expression levels of miR205-5p and miR126, and the size of the pulmonary nodule, wherein if the probability value exceeds a specified threshold, the pulmonary nodule is predicted as non-small cell lung cancer.Type: GrantFiled: April 5, 2018Date of Patent: December 27, 2022Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventor: Feng Jiang
-
Patent number: 11452685Abstract: A cosmetic composition and a method for preparing the cosmetic composition are provided. The cosmetic composition includes an aqueous phase and oil phase. The aqueous phase comprises at least one water soluble ingredient including at least one non-ionic surfactant. The oil phase comprises a transformative agent, at least one thickener and at least one solvent. The transformative agent comprising at least 1% of at least one butter and at least 1% of at least one oil, the transformative agent having a butter to oil ratio of from about 2:5 to about 9:10. The cosmetic composition has a transformative texture.Type: GrantFiled: October 30, 2017Date of Patent: September 27, 2022Assignee: L'OREALInventors: Susan Halpern Chirch, Victoria Shin-wei Fu, Mariana Montoya, Paul Bonvallet
-
Patent number: 11427873Abstract: A method for characterizing tumor response to immune checkpoint blockade therapy, comprising: (i) obtaining tissue from the tumor; (ii) measuring, using the tissue, expression of one or more cell proliferation gene markers; (iii) determining, based on the measured expression of the one or more cell proliferation gene markers, a proliferation profile of the tumor; (iv) predicting, based on the determined proliferation profile, response of the tumor to immune checkpoint blockade therapy; and (v) determining, by a physician using the predicted response of the tumor to immune checkpoint blockade therapy, a therapy for the tumor.Type: GrantFiled: August 9, 2019Date of Patent: August 30, 2022Assignee: OmniSeq, Inc.Inventors: Carl Morrison, Sarabjot Pabla, Jeffrey Conroy, Sean Glenn
-
Patent number: 11426073Abstract: Repetitive electrical activity produces microstructural alteration in myelinated axons. These transient microstructural changes can be non-invasively visualized via two different magnetic-resonance-based approaches: diffusion fMRI and dynamic T2 spectroscopy in the ex vivo perfused bullfrog sciatic nerves. Non-invasive diffusion fMRI, based on standard diffusion tensor imaging (DTI), clearly localized the sites of axonal conduction blockage as might be encountered in neurotrauma or other lesion types. Diffusion fMRI response was graded in proportion to the total number of electrical impulses carried through a given locus. Diffusion basis spectrum imaging (DBSI) method revealed a reversible shift of tissue water into a restricted isotropic diffusion signal component, consistent with sub-myelinic vacuole formation.Type: GrantFiled: April 29, 2019Date of Patent: August 30, 2022Assignee: Washington UniversityInventors: Sheng-Kwei Song, William M. Spees, Tsen-Hsuan Lin, Peng Sun, Chunyu Song
-
Patent number: 11268147Abstract: The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response.Type: GrantFiled: February 13, 2019Date of Patent: March 8, 2022Assignee: EWINGER, INC.Inventors: Edward E. Winger, Jane L. Reed
-
Patent number: 11219696Abstract: The present invention relates to Adeno-associated virus 9 methods and materials useful for systemically delivering polynucleotides across the blood brain barrier. Accordingly, the present invention also relates to methods and materials useful for systemically delivering polynucleotides to the central and peripheral nervous systems. The present invention also relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscle atrophy and amyotrophic lateral sclerosis as well as Pompe disease and lysosomal storage disorders. Use of the methods and materials is also indicated, for example, for treatment of Rett syndrome.Type: GrantFiled: May 20, 2015Date of Patent: January 11, 2022Assignee: NATIONWIDE CHILDREN'S HOSPITALInventors: Brian K. Kaspar, Kevin Foust
-
Patent number: 11209435Abstract: The present invention provides methods and compositions for identifying leukemic stem cells.Type: GrantFiled: March 4, 2019Date of Patent: December 28, 2021Assignee: The Charlotte-Mecklenburg Hospital AuthorityInventor: Jonathan M. Gerber
-
Patent number: 11202749Abstract: The present disclosure relates to HAPLN1 protein of an aged individual. The HAPLN1 protein exhibits reduced expression with aging, and when administered, its effect in alleviating and reversing skin aging including wrinkles is excellent. Therefore, by exploiting the difference in expression, provided are a biomarker composition for measuring skin aging, capable of diagnosing skin aging; a kit; and a method of screening for skin aging alleviating agents, comprising detecting the expression level of HAPLN1 protein or HAPLN1 gene. In addition, provided are a pharmaceutical composition, cosmetic composition, or health functional food for preventing or alleviating skin aging, and a cosmetic composition or health functional food for alleviating wrinkles, each containing any one or more selected from the group consisting of HAPLN1 protein, a gene encoding the same, and an effective agent for promoting the expression or activating the functions of HAPLN1 protein or gene.Type: GrantFiled: September 6, 2019Date of Patent: December 21, 2021Assignee: HAPLNSCIENCE INC.Inventors: Dae Kyong Kim, Zhicheng Fu, Moon Jung Back
-
Patent number: 11198715Abstract: Provided herein are compounds comprising peptides that bind Bfl-1. Also provided are compositions containing these peptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the peptides.Type: GrantFiled: July 21, 2017Date of Patent: December 14, 2021Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Amy Keating, Justin Michael Jenson
-
Patent number: 11181532Abstract: The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis.Type: GrantFiled: October 25, 2018Date of Patent: November 23, 2021Assignee: UNIVERSITÄT HEIDELBERGInventors: Dagmar Hildebrand, Klaus Heeg, Florian Uhle, Markus Weigand
-
Patent number: 11145412Abstract: A method for predicting the presence of melanoma comprises performing molecular profiling of at least one of genomic and transcriptomic material extracted from a skin swab sample collected from a lesion of a patient, extracting one or more biological features from the molecular profiling, comparing the one or more extracted biological features to one or more biological features corresponding to one or more reference skin swab samples collected from a plurality of reference patients, and predicting, based on the comparing, whether the lesion of the patient is cancerous.Type: GrantFiled: July 7, 2017Date of Patent: October 12, 2021Assignee: International Business Machines CorporationInventors: Thomas C. Conway, Ismael A. Vergara Correa
-
Patent number: 11096583Abstract: Methods, systems, and computer readable media for utilizing functional connectivity brain imaging for diagnosis of a neurobehavioral disorder are disclosed. One method for utilizing functional connectivity brain imaging for diagnosis of a neurobehavioral disorder includes receiving brain imaging data for a human subject of a first age, wherein the brain imaging data includes functional connectivity magnetic resonance imaging (fcMRI) data, and predicting, using at least one functional connection between brain locations in the fcMRI data, a neurobehavioral disorder diagnosis for the subject at a second age greater than the first age.Type: GrantFiled: December 28, 2018Date of Patent: August 24, 2021Assignees: The University of North Carolina at Chapel Hill, Washington UniversityInventors: Robert Wayne Emerson, Joseph Piven, Bradley Schlaggar, John Pruett, Jr.
-
Patent number: 11062808Abstract: System and method for assessing preterm delivery risk for pregnant subject is disclosed. Existing preterm delivery risk assessment methods provide results in late second or third trimester of pregnancy, so little time is available for medical advice. Presently disclosed method and system predict preterm delivery risk within 15 weeks of pregnancy. Microbiome characterization data obtained from microbiome sample from pregnant subject. ‘Microbial taxonomic abundance profile’ generated from microbiome characterization data, contains abundance values of microbes present in the microbiome sample. ‘Taxonomic Composition Skew’ value, and distribution characteristic value for ‘microbial taxonomic abundance profile’, quantifying biases in abundance values of microbes from the microbial taxonomic abundance profile, is computed.Type: GrantFiled: February 15, 2017Date of Patent: July 13, 2021Assignee: TATA CONSULTANCY SERVICES LIMITEDInventors: Sharmila Shekhar Mande, Mohammed Monzoorul Haque, Anirban Dutta, Nishal Kumar Pinna, Mitali Merchant
-
Patent number: 10877042Abstract: The invention provides anti-hypusine antibodies and their use in detecting and isolating polypeptides containing hypusine and/or deoxyhypusine, as well as compositions and kits comprising the anti-hypusine antibodies.Type: GrantFiled: February 27, 2018Date of Patent: December 29, 2020Assignee: Genentech, Inc.Inventors: Qianting Zhai, Paul J. Carter
-
Patent number: 10857194Abstract: A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.Type: GrantFiled: February 14, 2019Date of Patent: December 8, 2020Inventor: Shui Yin Lo
-
Patent number: 10639248Abstract: A solid water particle composition and method of use enhances the efficacy of a cosmetic item, a consumable liquid, and an organic liquid. The composition is based on a solid water particle phase of water. The composition consists of adding solid water particle composition to cosmetic item and a consumable liquid with or without replacing the pure water in the cosmetic item and consumable liquid, while at least one indigenous ingredient in the cosmetic item and consumable liquid remains substantially the same. The cosmetic item includes a cosmetic face mask and a cosmetic face cream. The consumable liquid includes an herbal drink. The solid water particle composition can also replace pure water in an organic liquid, such as alcoholic drink, organic solvent, liquid fuel, and paint. The cosmetic items and consumable liquids are enhanced by replacing pure water, with water having solid water particles and leaving ingredients substantially the same.Type: GrantFiled: December 27, 2016Date of Patent: May 5, 2020Inventor: Shui Yin Lo
-
Patent number: 10639288Abstract: Multi-step cosmetic regimens are provided to improve the appearance of aging skin. A target portion of skin that exhibits a sign of skin aging is identified. A first formulation is topically applied, comprising at least one active possessing an ability to transcriptionally up-regulate an eigengene derived from a genetic co-expression module for one or more biological themes associated with skin cleansing and/or skin detoxification, and/or skin hydration to the target portion of skin. A second formulation is also topically applied, comprising at least one active possessing an ability to transcriptionally up-regulate an eigengene derived from a co-expression module for one or more biological themes associated with skin repair and/or rebuilding to the target portion of skin.Type: GrantFiled: September 11, 2015Date of Patent: May 5, 2020Assignee: The Procter & Gamble CompanyInventors: Makio Tamura, Rosemarie Osborne, Heather Lynn Rocchetta
-
Patent number: 10598652Abstract: Disclosed herein are methods of using serum nitric oxide levels to diagnose subjects as having or likely to develop a post-operative complication.Type: GrantFiled: April 8, 2016Date of Patent: March 24, 2020Assignee: The Regents of the University of CaliforniaInventors: Hua Cai, Kimberly Howard-Quijano, Aman Mahajan, Ji Youn Youn
-
Patent number: 10585099Abstract: Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by SRM/MRM assay. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and a designated protein is quantitated in the digest sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the described peptides. The proteins that can be detected and/or quantitated are CD3D, B7H3, B7-2, STAT1, GBP1, GPNMB, CD27, CD3E, and CD8.Type: GrantFiled: November 13, 2017Date of Patent: March 10, 2020Assignee: EXPRESSION PATHOLOGY, INC.Inventors: Todd Hembrough, Fabiola Cecchi, Sarit Schwartz, Kerry Scott
-
Patent number: 10526662Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.Type: GrantFiled: March 19, 2018Date of Patent: January 7, 2020Assignee: Sutter Bay HospitalsInventors: Mohammed Kashani-Sabet, Altaf A. Dar
-
Patent number: 10308980Abstract: The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients.Type: GrantFiled: November 5, 2012Date of Patent: June 4, 2019Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Ragnhild A. Lothe, Trude Holmeide Agesen, Anita Sveen, Guro Elisabeth Lind, Arild Nesbakken, Rolf Inge Skotheim
-
Patent number: 10282514Abstract: A method of constructing a data architecture for use in identifying connections between perturbagens and genes associated with skin tone. The method includes providing a gene expression profile for a control cell, generating a gene expression profile for a cell exposed to a perturbagen, identifying genes differentially expressed in response to the perturbagen, creating an ordered list of identifiers, storing the ordered list as an instance on a computer readable medium, and constructing a data architecture of stored instances.Type: GrantFiled: March 27, 2013Date of Patent: May 7, 2019Assignee: The Procter & Gamble CompanyInventors: Tomohiro Hakozaki, Wenzhu Zhao, Robert Lloyd Binder, Jun Xu
-
Patent number: 10196591Abstract: Cleaning compositions in the form of a self-adhesive aqueous gel are provided. The aqueous gel may be a rigid, “hard” aqueous gel that resists deformation of its shape. The gel composition may desirably have a hardness of at least about 150 g and/or a gel melt temperature of about 50-90° C. The cleaning compositions may include a polyalkoxy nonionic surfactant, such as an alkoxylated alcohol and/or polymeric alkylene oxide block copolymer, a co-hardening agent, and water. Methods for treating a hard surface, such as a toilet bowl, using the cleaning compositions are also provided.Type: GrantFiled: June 28, 2016Date of Patent: February 5, 2019Assignee: S. C. Johnson & Sons, Inc.Inventors: Wayne M. Rees, Thomas A. Strash
-
Patent number: 9986723Abstract: The present disclosure relates to methods for screening compounds for treating pancreatic ductal adenocarcinoma (PDA) using a mouse model with an Rgs16::GFP reporter. Also described are combination therapies for treating pancreatic ductal adenocarcinoma (PDA) using taxanes, gemcitabine and an Axl kinase inhibitor.Type: GrantFiled: October 22, 2015Date of Patent: June 5, 2018Assignee: The Board of Regents of the University of Texas SystemInventors: Thomas M. Wilkie, Rolf A. Brekken
-
Patent number: 9486005Abstract: A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogs of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and/or a deleterious lipoprotein profile in an individual.Type: GrantFiled: February 22, 2011Date of Patent: November 8, 2016Inventors: Smiti Vaid Gupta, Enrique Martinez, II, Fazlul H. Sarkar, Denis M. Callewaert, Andreea Geamanu, Kevin Michael Patrie, Tiffany Capri Thomas, Andrew A. Dahl
-
Patent number: 9442119Abstract: Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: March 24, 2014Date of Patent: September 13, 2016Assignee: EXPRESSION PATHOLOGY, INC.Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Patent number: 9381176Abstract: Provided herein are methods for increasing insulin secretion from beta cells. Also provide herein are methods comprising administering to a subject in need of increased insulin secretion a composition comprising a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that attenuates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition.Type: GrantFiled: February 22, 2013Date of Patent: July 5, 2016Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Mark Keller, Alan Attie, Michelle Kimple
-
Patent number: 9320690Abstract: An encapsulated oral care composition includes: (a) a gelatin capsule; and (b) a oral care composition contained within the capsule, and including: (i) a hydrophilic active; (ii) a hydrophobic structuring agent; and (iii) an oil carrier. The hydrophilic active is preferably cetylpyridinium chloride. The hydrophobic structuring agent is preferably a gelled mineral oil. The oil carrier is preferably a vegetable oil. A method of cleaning teeth includes applying to the teeth the encapsulated oral care composition such that the capsule releases the oral care composition to clean the teeth. A oral care implement includes: a handle; a head mounted to the handle, the head having an outer surface and a plurality of tooth cleaning elements extending outwardly from the outer surface; and the encapsulated oral care composition positioned on the head.Type: GrantFiled: December 20, 2010Date of Patent: April 26, 2016Assignee: Colgate-Palmolive CompanyInventors: Dennis Kembero Ontumi, Thomas James Boyd, Suman Kumar Chopra, James Richard Brown
-
Patent number: 9260756Abstract: Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders.Type: GrantFiled: February 22, 2013Date of Patent: February 16, 2016Assignee: Children's Hospital Medical CenterInventors: Marc E. Rothenberg, Thomas Xuefeng Lu
-
Patent number: 9161891Abstract: A oral care composition includes: (a) a guanidine active; (b) a film-forming polymer; (c) a hydrophobic viscosity modifier in an amount sufficient to provide the oral care composition with a particle settling time greater than 20 minutes; and (d) an oil carrier. The guanidine active is preferably L-arginine. The film-forming polymer is preferably GANTREZ. The hydrophobic viscosity modifier is preferably a gelled mineral oil. The oil carrier is preferably a vegetable oil. A method of cleaning teeth includes applying to the teeth the oral care composition such that the oral care composition cleans the teeth. A oral care implement includes: a handle; a head mounted to the handle, the head having an outer surface and a plurality of tooth cleaning elements extending outwardly from the outer surface; and a gelatin capsule containing the oral care composition positioned on the head.Type: GrantFiled: December 20, 2010Date of Patent: October 20, 2015Assignee: Colgate-Palmolive CompanyInventors: Dennis Kembero Ontumi, Sarita Vera Mello, Suman Kumar Chopra, James Richard Brown, Thomas James Boyd, Rahul Patel
-
Publication number: 20150148432Abstract: The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases.Type: ApplicationFiled: July 14, 2014Publication date: May 28, 2015Inventor: Gregory S. Hageman
-
Publication number: 20150141529Abstract: A method for alleviating centralized pain in human subjects includes assessing the brain of a subject suffering from pain, diagnosing abnormal brain function associated with centralized pain, locating at least one area of abnormal brain function associated with the centralized pain, and alleviating the abnormal brain function by applying a cortical stimulation signal to tissues corresponding to the at least one area of abnormal brain function.Type: ApplicationFiled: May 8, 2013Publication date: May 21, 2015Inventor: Jeffrey B. Hargrove
-
Publication number: 20150141530Abstract: A method of characterizing melanoma in a subject involves determining the presence or level of one or more bio-markers in a sample obtained from a sentenal lymph node (SLN) of a subject.Type: ApplicationFiled: March 13, 2013Publication date: May 21, 2015Inventors: Hongying Hao, Kelly M. McMasters
-
Publication number: 20150141528Abstract: An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and/or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.Type: ApplicationFiled: June 2, 2014Publication date: May 21, 2015Applicant: BANYAN BIOMARKERS, INC.Inventor: Stephen Larner
-
Publication number: 20150126621Abstract: Described herein are miRNA-based methods for prognosis of recurrence of melanoma and related methods and kits. The present invention addresses these and other needs by providing a method for predicting the likelihood of recurrence of melanoma (including distal metastasis and locoregional recurrence) in a subject diagnosed with melanoma. In a separate aspect, the invention provides a method for treatment of a melanoma recurrence (including distal metastasis and locoregional recurrence) in a subject in need thereof.Type: ApplicationFiled: May 15, 2013Publication date: May 7, 2015Applicant: New York UniversityInventors: Douglas Hanniford, Eva Hernando-Monge, Iman Osman, Shulian Shang, Yongzhao Shao
-
Publication number: 20150126620Abstract: The present invention relates to improved methods and compounds for treating anemia. Screening methods to identify agents for use in these treatment methods are also provided.Type: ApplicationFiled: August 16, 2012Publication date: May 7, 2015Applicant: FibroGen, Inc.Inventors: Thomas B. Neff, David Liu, Gail Walkinshaw, Marja Johanna Myllyharju, Kari Ilkka Kivirikko, Peppi Leena Elina Karppinen
-
Publication number: 20150126622Abstract: Necrotizing Enterocolitis (NEC) biomarkers, NEC biomarker panels, and methods for obtaining a NEC signature for a sample are provided. Also provided are methods, compositions, and kits for making a Necrotizing Enterocolitis (NEC) assessment of an individual, e.g. for diagnosing NEC in a patient, prognosing NEC in a patient, treating an NEC patient, etc. These methods find use in a number of applications, such as diagnosing and treating infants who are suspected of having NEC, intestinal perforation (IP), or sepsis.Type: ApplicationFiled: June 10, 2013Publication date: May 7, 2015Inventors: Karl G. Sylvester, Guozhong Tao
-
Publication number: 20150126623Abstract: A method for treating depression using a biomarker includes measuring a level of phosphoethanolamine in a blood sample collected from a subject, comparing the level of phosphoethanolamine in the blood sample with a predetermined threshold, in response to the level of phosphoethanolamine in the blood sample being below the predetermined threshold, determining that the subject requires a treatment for depression, and treating the subject determined to suffer from depression.Type: ApplicationFiled: December 29, 2014Publication date: May 7, 2015Inventors: Noriyuki KAWAMURA, Kosaku SHINODA, Yoshiaki OHASHI, Takamasa ISHIKAWA, Hajime SATO
-
Publication number: 20150119476Abstract: Provided herein is a comprehensive characterization of a novel polyclonal antibody (IU-88) that specifically recognizes the hypusinated eIF5A. The antibody IU-88 is useful for the investigation of eIF5A biology, for the development of assays recognizing hypusinated eIF5A, and for methods of treating conditions and diseases that involve the activity of hypusinated eIF5A. The antibody was used to determine that the levels of hypusinated eIF5A were elevated in the pancreatic tissues of patients diagnosed with Type 1 or Type 2 Diabetes.Type: ApplicationFiled: August 20, 2014Publication date: April 30, 2015Inventor: Raghavendra G. Mirmira
-
Publication number: 20150119475Abstract: The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.Type: ApplicationFiled: May 2, 2013Publication date: April 30, 2015Inventors: Jim Lorens, Crina Tiron
-
Publication number: 20150112607Abstract: A rare disease matching and prediction portal is provided where a number of symptoms are matched with a list of rare diseases to produce candidate diseases, after which the candidate diseases are evaluated based on weighted lists of symptoms for each candidate disease to produce a confidence indicating a likelihood that a patient suffers from one of the rare diseases. Information curated from publications and other curated databases related to rare diseases are utilized to determine the weighted list of symptoms for each disease based on prevalence relevance of each symptom to each candidate disease, and a customized algorithm is applied to determine the confidences for the candidate diseases. Along with the confidences, the portal may provide a disease profile for each disease which includes possible treatments for the candidate diseases. The patient may then be treated for at least one of the candidate diseases based on the confidences.Type: ApplicationFiled: December 8, 2014Publication date: April 23, 2015Inventor: Hendrik Anton Meijer
-
Publication number: 20150099811Abstract: Various embodiments provide methods for the detection, the diagnosis, and/or the prediction of disease onset of Alzheimer's disease. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate, labeling the sample to identify at least one epigenetic marker and at least one of an inflammation marker and a cellular stress marker; determining an amount of the markers; performing a multivariate statistical analysis to produce an output value; comparing the output value to a reference value; and determining a state of Alzheimer's disease.Type: ApplicationFiled: December 11, 2014Publication date: April 9, 2015Inventor: Paul D. Coleman
-
Publication number: 20150093448Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Angiopoietin-related protein 3, Soluble Lymphatic vessel endothelial hyaluronic acid receptor 1, and Vascular endothelial growth factor D as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: December 17, 2014Publication date: April 2, 2015Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20150094384Abstract: Embodiments are presented herein that provide early prediction of the development of necrotizing enterocolitis by a preterm infant through analysis of the high frequency component of heart rate variability, optionally with analysis of respiration rate. Methods of treatment following prediction area also reported.Type: ApplicationFiled: March 13, 2013Publication date: April 2, 2015Inventors: Kim Kopenhaver Doheny, Charles Palmer
-
Publication number: 20150087727Abstract: An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.Type: ApplicationFiled: March 24, 2014Publication date: March 26, 2015Applicant: B.R.A.H.M.S GmbHInventors: Andreas BERGMANN, Joachim STRUCK, Nils G. MORGENTHALER, Jana PAPASSOTIRIOU, Stefan BLANKENBERG, Karl LACKNER, Hans RUPPRECHT, Christoph BICKEL